Research Programme: protein degradation therapeutics - UPPTHERA/Yuhan
Latest Information Update: 03 Mar 2023
At a glance
- Originator Yuhan
- Class Anti-inflammatories; Antidementias; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Inflammation